Analyst Estimates: Here's What Brokers Think Of Sabaf S.p.A. (BIT:SAB) After Its First-Quarter Report

Last week saw the newest first-quarter earnings release from Sabaf S.p.A. (BIT:SAB), an important milestone in the company's journey to build a stronger business. It was a credible result overall, with revenues of €74m and statutory earnings per share of €0.55 both in line with analyst estimates, showing that Sabaf is executing in line with expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the latest results, the twin analysts covering Sabaf are now predicting revenues of €290.9m in 2025. If met, this would reflect a reasonable 2.6% improvement in revenue compared to the last 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of €291.0m and earnings per share (EPS) of €1.15 in 2025. Overall, while the analysts have reconfirmed their revenue estimates, the consensus now no longer provides an EPS estimate. This implies that the market believes revenue is more important after these latest results.

Check out our latest analysis for Sabaf

We'd also point out that thatthe analysts have made no major changes to their price target of €21.00.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's pretty clear that there is an expectation that Sabaf's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 3.5% growth on an annualised basis. This is compared to a historical growth rate of 7.2% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 6.1% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Sabaf.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Sabaf's revenue is expected to perform worse than the wider industry. The consensus price target held steady at €21.00, with the latest estimates not enough to have an impact on their price targets.

At least one of Sabaf's twin analysts has provided estimates out to 2027, which can be seen for free on our platform here.

Even so, be aware that Sabaf is showing 4 warning signs in our investment analysis , and 1 of those is potentially serious...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.